ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix Pharmaceuticals announced positive interim Phase 3 data from the ProstACT Global study of TLX591-Tx, a lutetium-based radio antibody-drug conjugate, showing acceptable safety and tolerability when combined with standard of care therapies in metastatic castration-resistant prostate cancer. Part 2 of the trial is underway, and discussions with …